Mechanisms for the prevention of gastrointestinal cancer

The role of prostaglandin E2

Michael G. Backlund, Jason R. Mann, Raymond N. DuBois

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalOncology
Volume69
Issue numberSUPPL. 1
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Gastrointestinal Neoplasms
Dinoprostone
Colorectal Neoplasms
Anti-Inflammatory Agents
Prostaglandins
Pharmaceutical Preparations
Cyclooxygenase 1
Cyclooxygenase 2 Inhibitors
Polyps
Rectum
Colonic Neoplasms
Cell Movement
Epidemiologic Studies
Neoplasms
Protein Isoforms
Colon
Cell Death
Cell Proliferation
Carcinoma
Lipids

Keywords

  • 15-Hydroxyprostaglandin dehydrogenase
  • Colorectal cancer
  • Cyclooxygenase 2
  • Prostaglandin E

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mechanisms for the prevention of gastrointestinal cancer : The role of prostaglandin E2. / Backlund, Michael G.; Mann, Jason R.; DuBois, Raymond N.

In: Oncology, Vol. 69, No. SUPPL. 1, 2005, p. 28-32.

Research output: Contribution to journalArticle

Backlund, Michael G. ; Mann, Jason R. ; DuBois, Raymond N. / Mechanisms for the prevention of gastrointestinal cancer : The role of prostaglandin E2. In: Oncology. 2005 ; Vol. 69, No. SUPPL. 1. pp. 28-32.
@article{aacdf0be9dc04c4ea4cba5c2ce6cb790,
title = "Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2",
abstract = "Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.",
keywords = "15-Hydroxyprostaglandin dehydrogenase, Colorectal cancer, Cyclooxygenase 2, Prostaglandin E",
author = "Backlund, {Michael G.} and Mann, {Jason R.} and DuBois, {Raymond N.}",
year = "2005",
doi = "10.1159/000086629",
language = "English (US)",
volume = "69",
pages = "28--32",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Mechanisms for the prevention of gastrointestinal cancer

T2 - The role of prostaglandin E2

AU - Backlund, Michael G.

AU - Mann, Jason R.

AU - DuBois, Raymond N.

PY - 2005

Y1 - 2005

N2 - Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.

AB - Carcinoma of the colon or rectum represents one of the most common malignancies worldwide with a higher prevalence in industrialized regions. Epidemiologic studies of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs) have shown a significant reduction in colorectal cancer (CRC) mortality compared to those individuals not receiving these agents. NSAIDs inhibit the enzymatic activity of both isoforms of cyclooxygenase (COX-1 and COX-2), while COX-2-selective inhibitors have shown some efficacy in reducing polyp formation. COX-2-derived bioactive lipids, including the primary prostaglandin (PG) generated in colorectal tumors, PGE2, are known to stimulate cell migration, proliferation and tumor-associated neovascularization while inhibiting cell death. Here we briefly review the role of NSAIDs in preventing CRC, as well as the proposed mechanism by which a COX-2-derived PG, PGE2, promotes colon cancer.

KW - 15-Hydroxyprostaglandin dehydrogenase

KW - Colorectal cancer

KW - Cyclooxygenase 2

KW - Prostaglandin E

UR - http://www.scopus.com/inward/record.url?scp=26444543238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444543238&partnerID=8YFLogxK

U2 - 10.1159/000086629

DO - 10.1159/000086629

M3 - Article

VL - 69

SP - 28

EP - 32

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -